Quality of Life in Adults With Metastatic Breast Cancer: The Impact of Between‐ and Within‐Person Changes in Symptoms and Positive Affect
Brenna Mossman, Brent J. Small, Elizabeth L. Addington, Judith Tedlie Moskowitz, Mikaela A. Velazquez‐Sosa, Jennifer D. Rodriguez, Aigner Bobbitt, Alene Mathurin, Lesley Glenn, Shontè Drakeford, Roxana Guerra, Claudine Isaacs, Ami Chitalia, Christopher Gallagher, Deena Graham, Nina Kadan‐Lottick, Suzanne C. O'Neill, Claire C. ConleyABSTRACT
Introduction
Quality of life (QoL) is important for patients with metastatic breast cancer (MBC). We examined QoL in daily life among patients with MBC using ecological momentary assessment (EMA).
Methods
From 2023 to 2024, patients with MBC were recruited from 5 Mid‐Atlantic sites. Eligible patients were English‐ or Spanish‐speaking, with a life expectancy > 6 months and access to a smartphone. Participants were invited to complete 12 EMAs over 4 weeks. EMAs assessed global QoL, symptom severity (depression, anxiety, pain, fatigue, slowed cognition, appetite loss, nausea, gastrointestinal distress, decreased libido), and positive affect (social connection, peace, joy). Multilevel mixed‐effects models analyzed the relationships between QoL and between‐person and within‐person variations in symptom severity and positive affect. We also explored associations between QoL and years since MBC diagnosis at the time of study entry.
Results
Participants ( N = 108; Mean age 57.8 years) were a mean of 4.4 years post‐diagnosis (range = 0.06–20.65 years). Between‐person effects indicated QoL was worse among individuals reporting more nausea ( β = −0.109, p = 0.035) and less joy ( β = 0.593, p < 0.001). Within‐person effects indicated individuals' QoL was lower at times when they had more depression ( β = −0.177, p < 0.001), anxiety ( β = −0.049, p = 0.023), fatigue ( β = −0.052, p = 0.009), appetite loss ( β = −0.053, p = 0.028), and decreased libido ( β = −0.058, p = 0.036) and less social connectedness ( β = 0.091, p = 0.001), joy ( β = 0.055, p = 0.047), and peace ( β = 0.107, p < 0.001) than their personal average. QoL was not associated with years since MBC diagnosis ( β = 0.106, p = 0.956). Age ( β = 0.482, p = 0.013) and being partnered ( β = 13.356, p = 0.005) at baseline were positively associated with estimated QoL at MBC diagnosis. Changes in QoL per year since MBC diagnosis were positively associated with being employed at baseline ( β = 2.453, p < 0.001) and negatively associated with HR positive disease ( β = −1.334, p = 0.001).
Conclusions
Both within‐person and between‐person variations in symptom severity and positive affect are associated with QoL, highlighting the need for adaptive, targeted intervention strategies to optimize QoL for all patients.